Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIIIFc in previously untreated children with severe hemophilia A
NL-OMON45745Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- Jun 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efmoroctocog alfa in hemophilia A, sponsored by Sanofi. Primary endpoint: Occurrence of inhibitor development. Planned start Jun 2016; status: withdrawn.
02
Drugs
efmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON45745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45745.